Palmoplantar Psoriasis
7
0
0
4
Key Insights
Highlights
Success Rate
80% trial completion
Clinical Risk Assessment
Based on trial outcomes
Low Risk
Score: 27/100
14.3%
1 terminated out of 7 trials
80.0%
-6.5% vs benchmark
71%
5 trials in Phase 3/4
100%
4 of 4 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 4 completed trials
Clinical Trials (7)
A Study to Evaluate Effectiveness and Safety of Deucravacitinib in Participants With Non-Pustular Palmoplantar and Genital Psoriasis
Real-World Study of Xeligekimab for Moderate to Severe Plaque Psoriasis(XP-Real)
Combination of Halobetasol Propionate and Tazarotene Lotion (Duobrii®) for Palmoplantar Plaque Type Psoriasis
Brodalumab in Palmoplantar Psoriasis
Apremilast in Palmo-Plantar Psoriasis
Efficacy Study of TEPSO® Socks in Improving Palmoplantar Psoriasis
Safety and Efficacy of Infliximab in Palmoplantar Psoriasis